As legal access to psilocybin expands, one question comes up again and again:
“Can I use psilocybin if I’m taking an antidepressant?”
The answer is more complicated, and more interesting, than a simple yes or no. For years, many psychedelic research studies excluded people taking selective serotonin reuptake inhibitors (SSRIs) and other antidepressants. This was partly because researchers were concerned about possible serotonin toxicity and partly because antidepressants might alter the psychedelic experience.
New research is beginning to challenge some of those assumptions.
At the same time, this does not mean that every medication can safely be combined with psilocybin. Different medications interact with serotonin in very different ways. MAOIs deserve particular caution, antidepressant discontinuation carries its own risks, and newer medications such as GLP-1 receptor agonists introduce questions that researchers have barely begun to study.
The most important message throughout this guide is simple:
Do not stop, skip, taper, increase, or otherwise change a prescription medication in order to use psilocybin without discussing it with the clinician who prescribes that medication.
This article is educational and is not a substitute for individualized medical advice.
Psilocybin itself is essentially a prodrug. After ingestion, it is rapidly converted into its pharmacologically active metabolite, psilocin.
A 2025 systematic review of psilocybin pharmacokinetics found that psilocybin is rapidly dephosphorylated into psilocin. Across the human studies reviewed, psilocin generally reached maximum blood concentrations approximately 1.8 to 4 hours after oral administration, although considerable individual variability exists (Meshkat et al., 2025).
Psilocin interacts with several serotonin receptors, but activation of the 5-HT2A receptor is particularly important to the characteristic psychedelic effects of psilocybin (Heal et al., 2026).
A simplified pathway looks like this:
Psilocybin → Psilocin → 5-HT2A receptor activation → changes in perception, cognition, emotion and brain-network activity
This is also where the emerging conversation about psychedelic-induced neuroplasticity becomes interesting. Contemporary research is examining psychedelic-associated changes in dendrites, dendritic spines and synaptic connectivity and the degree to which 5-HT2A signaling contributes to these effects. The exact mechanisms remain an active area of investigation rather than a completely settled question (Moliner et al., 2025).
That does not mean psilocybin simply “adds serotonin” to the brain.
And that distinction becomes extremely important when we start talking about antidepressants.
SSRIs include medications such as:
SSRIs primarily work by inhibiting the serotonin transporter, or SERT, reducing serotonin reuptake and changing serotonergic signaling.
Psilocin primarily produces its psychedelic effects through serotonin receptor activity, particularly 5-HT2A receptor activation.
So although both involve the serotonin system:
SSRI → serotonin transporter
and
Psilocin → serotonin receptors, especially 5-HT2A
are not pharmacologically identical processes.
Chronic antidepressant treatment may also produce downstream adaptations in serotonin receptors and signaling. This has contributed to the hypothesis that some antidepressants might attenuate the subjective effects of psychedelics.
But does that actually happen?
The answer appears to be:
This is one of the most interesting areas of current research because different types of evidence have produced different results.
Becker and colleagues conducted a randomized, double-blind, placebo-controlled crossover study in healthy participants.
Participants received either escitalopram or placebo for 14 days before receiving 25 mg of psilocybin.
Contrary to what many people might expect, escitalopram pretreatment had no relevant effect on the positive mood effects of psilocybin.
It actually reduced several undesirable responses, including anxiety, negative drug effects and adverse cardiovascular effects (Becker et al., 2022).
That is important evidence against the simplistic claim that:
“SSRIs block psilocybin.”
But this was a small controlled study involving healthy participants and one particular SSRI. It does not establish that every SSRI, dose, duration of treatment or individual will respond identically.
Gukasyan and colleagues collected retrospective reports from people who had taken psilocybin mushrooms while using antidepressants.
Among 611 reports involving concurrent antidepressant use, the estimated probability of experiencing weaker-than-expected mushroom effects was:
47% with SSRIs, 55% with SNRIs, 29% with bupropion (Gukasyan et al., 2023).
Participants also reported that attenuation sometimes persisted after discontinuing an SSRI or SNRI, but there is a major methodological difference here. The Becker study was a controlled experiment using a standardized psilocybin dose. The Gukasyan study was a retrospective survey involving people’s previous experiences with psilocybin-containing mushrooms.
That means variables such as mushroom potency, dose accuracy, expectations, individual biology and memory could not be controlled in the same way. Neither study should simply be ignored because it conflicts with the other. Instead, together they tell us:
A recent scoping review examined studies involving concomitant use of antidepressants and classic psychedelics.
The authors concluded that the available evidence generally suggests antidepressants and classic psychedelics have been well tolerated, without robust evidence of increased serotonin syndrome risk, particularly with psilocybin. Some studies found attenuation of psychedelic effects, while others did not.
Importantly, the authors also questioned whether routinely requiring people to discontinue antidepressants before psychedelic treatment is always justified, particularly because discontinuation itself can carry risks (Do et al., 2025).
This is still an evolving area of research.
It should not be interpreted as:
“Every SSRI is safe with psilocybin.”
A more scientifically accurate interpretation is:
Existing human evidence is more reassuring than earlier assumptions suggested, but medication-specific and patient-specific evidence remains incomplete.
That’s exactly why a prescribing clinician should be involved.
This is an especially important harm-reduction question.
A person taking an SSRI may experience reduced psychedelic effects.
But medication is only one possible explanation.
Differences in subjective response may also involve:
Therefore, a muted experience should not automatically be interpreted as permission to keep increasing the amount consumed.
The safest response is to document what happened and discuss medication interactions with the appropriate clinician before changing the plan.
Most importantly:
This decision belongs with the person prescribing the antidepressant.
There are two separate questions here:
1. Could the antidepressant affect the psilocybin experience?
Possibly.
2. Does that mean discontinuing the antidepressant is beneficial?
Not necessarily.
In an exploratory analysis of a clinical psilocybin trial, participants who had recently discontinued serotonergic antidepressants actually showed reduced treatment effects compared with participants who entered the trial unmedicated.
The investigators were careful to emphasize that the study could not establish that discontinuation caused the poorer response (Erritzoe et al., 2024).
Interestingly, another post hoc analysis using data from a larger phase II trial reached a different conclusion: antidepressant discontinuation did not appear to compromise either psilocybin efficacy or the subjective psychedelic experience. The investigators disclosed that the analysis was funded by the company developing the psilocybin formulation and that the authors were employees/shareholders, another piece of context worth considering when evaluating the evidence (Goodwin et al., 2024).
Again, science is giving us nuance rather than a convenient universal rule.
Abruptly stopping an antidepressant, skipping doses or reducing the dose too quickly can produce withdrawal symptoms.
According to the UK’s National Institute for Health and Care Excellence (NICE), symptoms can include:
NICE recommends that people who want to discontinue an antidepressant speak with the clinician who prescribed it and that the dose usually be reduced in stages over time.
The appropriate process depends on the medication’s pharmacokinetics, treatment duration, individual response and withdrawal symptoms.
For some people, successful discontinuation can take weeks or months (NICE, 2022).
This is why we don’t recommend a universal “two-week washout” or DIY taper schedule.
This subject causes a tremendous amount of confusion around psychedelics.
Serotonin syndrome, more accurately described within the spectrum of serotonin toxicity, occurs when serotonergic activity becomes excessive.
Because psilocybin acts on serotonin receptors and SSRIs affect serotonin signaling, it is understandable that people assume combining them automatically causes serotonin syndrome.
Current pharmacologic evidence does not support that simple conclusion.
Malcolm and Thomas reviewed serotonin toxicity associated with serotonergic psychedelics and concluded:
“True ST typically occurs with a serotonergic drug overdose”
or when a serotonin-increasing drug is combined with an MAOI (Malcolm & Thomas, 2022).
The authors characterized non-MAOI serotonergic psychiatric medications combined with non-MAOI psychedelics as comparatively low risk for serotonin toxicity.
The more recent scoping review likewise found no robust evidence of increased serotonin syndrome risk from concomitant antidepressants and classic psychedelics, particularly psilocybin, while emphasizing the limitations of the existing literature.
This makes recognizing an emergency tricky.
Psilocybin can produce:
Those symptoms alone do not establish serotonin syndrome.
More concerning symptoms identified in the serotonin-toxicity literature include:
(Malcolm & Thomas, 2022).
If severe or rapidly escalating symptoms occur, seek emergency medical care.
Don’t try to diagnose or treat suspected serotonin toxicity yourself.
This is where the conversation changes considerably.
MAOI stands for monoamine oxidase inhibitor.
Prescription MAOIs include medications such as:
Monoamine oxidase metabolizes monoamine neurotransmitters. Inhibiting this enzyme creates interaction possibilities that are substantially different from those associated with SSRIs. A published case illustrates why caution is warranted.
A 42-year-old man taking the MAOI tranylcypromine as well as extended-release dextroamphetamine-amphetamine consumed Psilocybe cubensis mushrooms. Approximately 30 minutes later, he developed severe hypertension, chest pain, palpitations, and headache and required emergency hospital treatment.
The authors hypothesized that phenylethylamine compounds present in whole mushrooms may have interacted with the MAOI and the stimulant, rather than attributing the event solely to psilocybin (Barnett et al., 2025).
That distinction is fascinating pharmacologically, but it doesn’t change the practical message:
Do not discontinue an MAOI or attempt to calculate your own washout period.
People sometimes assume that replacing a pharmaceutical with an herb automatically reduces interaction risk.
Plants contain pharmacologically active compounds too.
Some can interact with exactly the same neurotransmitter and metabolic systems affected by prescription medications.
That brings us to two herbs frequently discussed in psychedelic and wellness communities.
Kanna, Sceletium tortuosum, is a South African botanical containing mesembrine-type alkaloids.
Research indicates several potentially relevant pharmacological mechanisms, including serotonin transporter inhibition and PDE4 inhibition. Other mechanisms involving monoamine signaling have also been investigated (Olatunji et al., 2021).
This is precisely why kanna should not simply be described as an herbal tool for “getting off an SSRI.”
Its pharmacology overlaps with systems affected by psychiatric medications.
We currently do not have strong clinical evidence establishing kanna as an effective treatment for SSRI withdrawal.
If someone taking an antidepressant is considering kanna, the safest approach is to have their medication and supplement combination reviewed by their physician, prescribing clinician or pharmacist.
Kava, Piper methysticum, has a very different pharmacological profile.
There is human research examining kava for anxiety. NCCIH reports that kava supplements may have some benefit for anxiety, although the evidence is not definitive across anxiety disorders.
That’s different from saying:
“Kava treats antidepressant withdrawal.”
There currently isn’t sufficient evidence to make that claim.
Kava also isn’t risk-free. Products containing kava have been associated with rare cases of serious liver injury, and it can interact with sedating substances. NCCIH recommends that people taking medications discuss kava with a healthcare professional.
So kava might be a botanical that a qualified clinician considers in an individual’s broader care plan, but it should not be marketed as a replacement for supervised antidepressant discontinuation.
Two examples are particularly worth mentioning.
St. John’s wort has significant drug-interaction potential because it affects drug-metabolizing enzymes and transport proteins.
NCCIH specifically warns that combining St. John’s wort with certain antidepressants can increase serotonin-related adverse effects and potentially produce serious interactions.
5-hydroxytryptophan, or 5-HTP, is a serotonin precursor.
Memorial Sloan Kettering advises that people taking SSRIs, MAOIs, tricyclic antidepressants and other serotonergic medications should not use 5-HTP without supervision from the treating clinician because of potential serotonergic toxicity.
Adding several “natural” serotonin-supporting supplements while simultaneously changing an antidepressant may actually make the pharmacologic picture more complicated, not less.
Not a particular herb.
The strongest clinical guidance supports an individualized, gradual taper supervised by the prescribing clinician, with monitoring and adjustment based on withdrawal symptoms.
NICE recommends stepwise dose reduction and notes that smaller reductions may become appropriate as the dose becomes lower. The pace should be agreed upon with the person taking the medication, and subsequent reductions should generally wait until withdrawal symptoms have resolved or become tolerable.
Psychological support, adequate sleep, movement, stress-management practices and other supportive care may be valuable during the process, but they don’t substitute for medication management.
If complementary medicine is part of someone’s plan, a clinician or pharmacist should review the herbs and supplements alongside the medication list.
This is one of the newest questions arising around psychedelic medicine.
GLP-1 receptor agonists include medications containing semaglutide, while medications such as tirzepatideadditionally target GIP receptors.
These medications can affect gastric motility.
A systematic review examining GLP-1 receptor agonists and orally administered medications found that GLP-1 therapy commonly resulted in a delayed time to maximum drug concentration (Tmax) and sometimes a reduced maximum concentration (Cmax).
Importantly, overall drug exposure generally was not altered to a clinically significant degree for the medications studied (Hauge et al., 2024).
A separate systematic review and meta-analysis also documented delayed gastric emptying associated with GLP-1 agonists.
This distinction matters.
We have evidence that GLP-1 therapies can alter gastric emptying.
We have pharmacokinetic evidence showing that orally administered psilocybin is converted to psilocin and that psilocin typically reaches peak blood concentrations within the first several hours.
But we do not currently have good clinical trials directly demonstrating how semaglutide or tirzepatide changes psilocybin pharmacokinetics.
It is therefore biologically plausible that delayed gastric emptying could alter the timing of an orally consumed psychedelic experience.
That is an inference, not an established clinical finding.
We should not tell someone:
“Your GLP-1 will make psilocybin take longer.”
We can say:
“Because GLP-1 medications can slow gastric emptying, altered timing of oral psilocybin is plausible, but this interaction has not been adequately studied.”
There is another practical consideration.
GLP-1 medications commonly produce gastrointestinal effects, and psilocybin can also cause nausea and gastrointestinal discomfort.
Someone using a GLP-1 should therefore disclose that medication to their healthcare team before a psilocybin experience.
Sometimes people hesitate to tell their physician that they are considering psilocybin.
But your prescriber knows something your facilitator may not:
your complete medical history.
They know why a medication was prescribed, how long you’ve taken it, previous medication responses, cardiovascular considerations and other factors that may materially change the risk calculation.
You can simply say:
“I’m considering participating in a legal psilocybin experience. I don’t want to change any of my medications without medical guidance. Can you review my prescriptions and supplements for possible interactions and tell me whether you have any concerns?”
Useful questions include:
Is there a known interaction between my medications and psilocybin?
Could my medication alter the effects?
Is there any medical reason psilocybin would be inappropriate for me?
Do any of my supplements affect serotonin or monoamine metabolism?
What symptoms would you want me to seek medical attention for?
If I independently want to discontinue my antidepressant for my overall treatment goals, what would a medically supervised process look like?
That last question is intentionally different from:
“How fast can I get off this so the mushrooms work?”
Medication decisions deserve to be made around someone’s overall health, not around maximizing a psychedelic effect.
The relationship between psilocybin and psychiatric medications is more nuanced than much of the information circulating online suggests.
SSRIs: Current evidence does not establish that SSRIs automatically make psilocybin dangerous. Some evidence suggests they can attenuate psychedelic effects, while controlled research has not consistently demonstrated this.
Serotonin syndrome: Psilocybin plus an SSRI should not automatically be equated with serotonin syndrome. The pharmacologic literature suggests substantially greater concern with serotonergic overdose and combinations involving MAO inhibition, although research on psychedelic-medication interactions remains incomplete.
MAOIs: These require substantially greater caution because monoamine oxidase inhibition changes the interaction landscape. A published hypertensive-emergency case involving psilocybin mushrooms, tranylcypromine and a stimulant reinforces the need for medical review.
Stopping antidepressants: Do not abruptly discontinue or independently taper an antidepressant for a psychedelic experience. Evidence-based guidance supports individualized, staged withdrawal under clinical supervision.
Kanna: Kanna has pharmacologically relevant effects on serotonin signaling and is not an established substitute for an SSRI taper.
Kava: Kava has some evidence relating to anxiety but not sufficient evidence establishing it as a treatment for antidepressant withdrawal, and it carries its own safety considerations.
GLP-1 medications: Delayed gastric emptying makes altered oral-drug timing biologically plausible, but direct studies of GLP-1 medications with psilocybin are lacking. Don’t turn a plausible mechanism into a proven interaction.
And perhaps the most important takeaway:
It’s about understanding the individual’s medications, physiology, health history and goals, recognizing where the evidence is strong and where it isn’t, and involving appropriately qualified healthcare professionals when medical decisions are involved.
Talk to your prescribing clinician. Tell your facilitator what you take. Don’t hide supplements because they’re “natural.” And don’t change prescription medication simply to intensify a psychedelic experience.
Becker, A. M., Holze, F., Grandinetti, T., et al. (2022). Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clinical Pharmacology & Therapeutics, 111(4), 886–895. https://pubmed.ncbi.nlm.nih.gov/34743319/
Barnett, B. S., Koons, C. J., Van den Eynde, V., Gillman, P. K., & Bodkin, J. A. (2025). Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. Journal of Psychoactive Drugs, 57(3), 297–303. https://pubmed.ncbi.nlm.nih.gov/38903003/
Erritzoe, D., Barba, T., Spriggs, M. J., et al. (2024). Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/38520045/
Goodwin, G. M., et al. (2024). The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/39427449/
Gukasyan, N., et al. (2023). Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology, 37(7), 707–716. https://pubmed.ncbi.nlm.nih.gov/37291890/
Malcolm, B., & Thomas, K. (2022). Serotonin toxicity of serotonergic psychedelics. Psychopharmacology, 239(6), 1881–1891. https://pubmed.ncbi.nlm.nih.gov/34251464/
Meshkat, S., Al-Shamali, H., Perivolaris, A., et al. (2025). Pharmacokinetics of psilocybin: A systematic review. Pharmaceutics, 17(4), 411. https://pubmed.ncbi.nlm.nih.gov/40284409/
Olatunji, T. L., et al. (2021). Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological and clinical activities. Journal of Ethnopharmacology. https://www.sciencedirect.com/science/article/abs/pii/S0378874121007054
National Institute for Health and Care Excellence (NICE). (2022). Depression in adults: treatment and management. Recommendations on stopping antidepressant medication. https://www.nice.org.uk/guidance/ng222/chapter/Recommendations
National Center for Complementary and Integrative Health (NCCIH). Kava: Usefulness and safety. https://www.nccih.nih.gov/health/kava
National Center for Complementary and Integrative Health (NCCIH). Herb-drug interactions: What the science says. https://www.nccih.nih.gov/health/providers/digest/herb-drug-interactions-science
Memorial Sloan Kettering Cancer Center. 5-HTP. About Herbs, Botanicals & Other Products. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/5-htp-01
Systematic review of GLP-1 receptor agonist drug interactions (2024). Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications. Drug Safety. https://link.springer.com/article/10.1007/s40264-023-01392-3
Systematic review and meta-analysis of GLP-1 agonists and gastric emptying (2024). Quantified metrics of gastric emptying delay by GLP-1 agonists. American Journal of Gastroenterology, 119(6), 1126–1140. https://pmc.ncbi.nlm.nih.gov/articles/PMC11150091/
